depemokimab
Jump to navigation
Jump to search
Indications
Dosage
- 100 mg subcutaneously twice yearly
Mechanism of action
- binds to & inhibits interleukin-5
More general terms
References
- ↑ Jackson DJ et al Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med 2024. Sept 9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/39248309 https://www.nejm.org/doi/full/10.1056/NEJMoa2406673